The facts
Isomorphic Labs at a glance.
Read Oct 20, 2026. Valuations and amounts are copied as each source states them; a figure that is only reported (talks, or people familiar with the deal) is labeled as reported.
- Kind of company
- Drug discovery and biologyAI that designs drugs, proteins and antibodies.
- Based in
- London, United Kingdom
- Founded
- 2021Isomorphic Labs press release (company), May 12, 2026
- Last closed-round valuation
- No confirmed valuation
- Reported valuation
- Reported $40B–50B, in talks$40 billion to $50 billion (reported) (SiliconANGLE, citing Bloomberg, Oct 8, 2026)
- What it has shipped
- Research only so far
Founders
- Demis Hassabis: CEO; also heads Google DeepMind, from which Isomorphic was spun off (Reuters (via Yahoo Finance), Jeffrey Dastin and Deborah Sophia, Jan 20, 2026)
Bloomberg reported Isomorphic was in early talks to raise at a $40B-$50B valuation (via SiliconANGLE; round size and investors not disclosed). Oct 8, 2026
SiliconANGLE, citing Bloomberg, Oct 8, 2026
What it has built
Shipped, or not yet.
“Research only so far” is what our search found: something the public can use or buy, a model or API, research only, or nothing public.
IsoDDE, the company's internal AI drug design engine (not sold publicly; company performance claims reported by SiliconANGLE)
Source3 rounds
Funding, as reported.
Every round we found, with the amount, valuation and investors as the source states them.
| When | Round | Amount | Valuation | Investors named | Source |
|---|---|---|---|---|---|
| Mar 2025 | First external round | $600 million | Not stated | Thrive Capital (lead) | Reuters (via Yahoo Finance), Jeffrey Dastin and Deborah Sophia |
| May 12, 2026 | Series B | $2.1 billion | Not stated | Thrive Capital (lead), Alphabet, GV, MGX, Temasek, CapitalG, UK Sovereign AI Fund | Isomorphic Labs press release (company) |
| Oct 8, 2026 | New round (early talks; not confirmed) | not disclosed | $40 billion to $50 billion (reported) | None named | SiliconANGLE, citing Bloomberg |
Outside checks
What others have found.
- Peer-reviewed: 'Accurate structure prediction of biomolecular interactions with AlphaFold 3', Nature 630, 493-500, doi:10.1038/s41586-024-07487-w (joint DeepMind/Isomorphic work). (Nature 630, 493-500 (record via RePEc/IDEAS), Jun 2024)
Our note: Alphabet-backed spinoff of Google DeepMind (Alphabet invests directly), so it sits at the edge of 'not a big-tech division'. No clinical trial registry entry was found; in Jan 2026 Hassabis said it "expects to have its first clinical trials by the end of 2026" after earlier targeting end-2025 (Reuters). Partnerships with Eli Lilly and Novartis (2024) and Johnson & Johnson (Jan 2026) per SiliconANGLE. No valuation for the May 2026 round was found in a trusted source.
More drug discovery and biology